Marc Fila

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Larry A. Greenbaum, Marc Fila, Gianluigi Ardissino et al. · Kidney International · 2016 · 286 citations · Full text

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

Fádi Fakhouri, Marc Fila, François Provôt et al. · Clinical Journal of the American Society of Nephrology · 2016 · 176 citations · Full text

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Fádi Fakhouri, Marc Fila, Aurélie Hummel et al. · Blood · 2020 · 162 citations · Full text

Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients

Dominique P. Germain, Alain Fouilhoux, Stéphane Decramer et al. · Clinical Genetics · 2019 · 155 citations · Full text

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

Cécile Couchoud, Florian Bayer, Carole Ayav et al. · Kidney International · 2020 · 150 citations · Full text

Hemodialysis, Medicine, Covid-19 Pandemic +9